title: Adjuvant treatment.
abstract: Exocrine pancreatic cancer (pancreatic ductal adenocarcinoma) is one of the leading causes of cancer deaths in the western world, accounting for 5% of all cancer-related deaths. Only a small percentage of patients with pancreatic cancer are able to undergo potentially curative resection, even in specialized centres, and prognosis remains poor after successful surgery. Over the last few years efforts have been directed towards the development of adjuvant therapies in attempts to improve outcome. The main trials of adjuvant chemotherapy, chemoradiotherapy and chemoradiotherapy with follow-on chemotherapy are described in this paper, followed by the results of the ESPAC-1 trial and the status of ESPAC-2 and -3 trials.
authors.affiliation: Division of Surgery and Oncology, University of Liverpool, Liverpool, UK.
authors.forename: Asma
authors.initials: A
authors.lastname: Sultana
authors.forename: John
authors.initials: J
authors.lastname: Neoptolemos
authors.forename: Paula
authors.initials: P
authors.lastname: Ghaneh